.jpg)
.jpg)
University of California, San Francisco
Thomas Hope, MD, is the Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is also the Associate Chair for Business Strategy for Radiology. He serves as Chief of Nuclear Medicine at the San Francisco VA Medical Center. He also serves as chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee. In 2007, he received his medical degree from Stanford University School of Medicine and he completed a one-year internship at Kaiser Permanente, San Francisco. From 2008-2012, Dr. Hope completed a residency in Diagnostic Radiology at the University of California, San Francisco, followed by a clinical fellowship in Body MRI and Nuclear Medicine from Stanford Medical Center in 2013. Dr. Hope’s main research focus is on novel imaging agents and therapies, particularly in prostate cancer and neuroendocrine tumors. He lead the development of Ga-68 PSMA-11, which subsequently led to the approval of this drug by the FDA. He has combined his interest in MR imaging with PET in the simultaneous modality PET/MRI, helping lead the development of the clinical PET/MRI program. Additionally he leads the PRRT (peptide receptor radionuclide therapy) program for neuroendocrine tumors and PSMA Radioligand Therapy at UCSF.
Disclosure information not submitted.